Merck (BSP:MRCK34) 3-Year EPS without NRI Growth Rate : -20.20% (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is Merck 3-Year EPS without NRI Growth Rate?

Merck's EPS without NRI for the three months ended in Dec. 2023 was R$0.02.

During the past 12 months, Merck's average EPS without NRI Growth Rate was -79.80% per year. During the past 3 years, the average EPS without NRI Growth Rate was -20.20% per year. During the past 5 years, the average EPS without NRI Growth Rate was -6.90% per year. During the past 10 years, the average EPS without NRI Growth Rate was -0.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Merck was 39.10% per year. The lowest was -20.20% per year. And the median was 7.60% per year.

Competitive Comparison of Merck's 3-Year EPS without NRI Growth Rate

For the Drug Manufacturers - General subindustry, Merck's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Merck's 3-Year EPS without NRI Growth Rate Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Merck's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Merck's 3-Year EPS without NRI Growth Rate falls into.

Merck 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

Merck (BSP:MRCK34) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.

Merck 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Merck's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Merck (BSP:MRCK34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Merck & Co Inc (BSP:MRCK34) » Definitions » 3-Year EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

MRK:USA MRK:Peru MRK:Mexico 1MRKX:Italy 6MKd:UK 0QAH:UK 6MK:Germany MRK:Chile MRK:Austria MRK:Argentina

Address

126 East Lincoln Avenue, Rahway, NJ, USA, 07065

Website

https://www.merck.com

Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent pediatric diseases as well as human papillomavirus, or HPV. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the company's sales are generated in the United States.

Merck (BSP:MRCK34) Headlines

No Headlines